Trial Profile
A study of rivaroxaban and apixaban in atrial fibrillation patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
- Indications Embolism and thrombosis
- Focus Therapeutic Use
- 17 Jan 2018 New trial record.